(3S)-4-methylaminomethyl-2-(3-methyl-2,6-dioxo-piperidin-3-yl)isoindole-1,3-dione hydrochloride | 1010100-30-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (3S)-4-methylaminomethyl-2-(3-methyl-2,6-dioxo-piperidin-3-yl)isoindole-1,3-dione hydrochloride
• 英文别名: 4-(methylaminomethyl)-2-[(3S)-3-methyl-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione;hydrochloride
• CAS: 1010100-30-7
• 化学式: C₁₆H₁₇N₃O₄*ClH
• 分子量: 351.79
• InChiKey: OBPBNIQFIBKYBM-NTISSMGPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.62
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  95.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3S)-4-methylaminomethyl-2-(3-methyl-2,6-dioxo-piperidin-3-yl)isoindole-1,3-dione hydrochloride 、 3-甲氧基苯异氰酸 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以74%的产率得到(3S)-3-(3-methoxy-phenyl)-1-methyl-1-[2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea
  参考文献：
  名称：

  WO2008/27542

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl-[2-((S)-3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-carbamic acid tert-butyl ester 在 盐酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 以87%的产率得到(3S)-4-methylaminomethyl-2-(3-methyl-2,6-dioxo-piperidin-3-yl)isoindole-1,3-dione hydrochloride
  参考文献：
  名称：

  WO2008/27542

  摘要：

  公开号：

文献信息

• 5-SUBSTITUTED ISOINDOLINE COMPOUNDS
  申请人：CELGENE CORPORATION

  公开号：US20150005303A1

  公开（公告）日：2015-01-01

  This invention relates to 5-substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  本发明涉及5-取代的异吲哚啉化合物，以及其药物可接受的盐，溶剂化物，立体异构体和前药。本发明还揭示了这些化合物的使用方法和制药组合物。
• 5-substituted isoindoline compounds
  申请人：CELGENE CORPORATION

  公开号：EP2749559A1

  公开（公告）日：2014-07-02

  The present invention relates to 5-substituted isoindoline compounds of formula (III) or formula (IV) wherein R10, R11, R13, R14, X and Y are as defined herein; or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof. The present invention also relates to a pharmaceutical composition of the compounds of the invention. The present invention also relates to a compound of the invention for use in treating, managing or preventing disease conditions as disclosed herein.

  本发明涉及式 (III) 的 5-取代异吲哚啉化合物 或式（IV） 其中R10、R11、R13、R14、X和Y如本文所定义；或其药学上可接受的盐、溶液、立体异构体或原药。本发明还涉及本发明化合物的药物组合物。本发明还涉及用于治疗、控制或预防本文所公开的疾病状况的本发明化合物。
• METHOD FOR PRODUCING PURIFIED SOLUTION OF COMPLEXES HAVING OXALIC ACID AS LIGAND IN NON-AQUEOUS SOLVENT
  申请人：Central Glass Co., Ltd.

  公开号：EP2857406B1

  公开（公告）日：2017-08-23
• Purified Metal Complex Having Oxalic Acid as Ligand, and Method For Producing Purified Solution of Said Metal Complex in Non-Aqueous Solvent
  申请人：Central Glass Co., Ltd.

  公开号：US20150147643A1

  公开（公告）日：2015-05-28

  The present invention provides a purified metal complex having oxalic acid as a ligand and a method for industrially producing a purified non-aqueous solvent solution of the metal complex at low cost. In the method of the present invention, oxalic acid contained in a non-aqueous solvent solution of a metal complex having oxalic acid as a ligand is decomposed by a reaction with a thionyl halide in a non-aqueous solvent, and the decomposition product of the reaction and the unreacted thionyl halide are removed by deaeration.
• USE OF REACTIVE LITHIUM ALKOXYBORATES AS ELECTROLYTE ADDITIVES IN ELECTROLYTES FOR LITHIUM ION BATTERIES
  申请人：BASF SE

  公开号：US20160164142A1

  公开（公告）日：2016-06-09

  An electrolyte composition (A) containing (i) at least one aprotic organic solvent, (ii) at least one conducting salt different from the at least one compound of formula (I), (iii) at least one compound of formula (I), wherein R 1 , R 2 , R 3 , and R 4 are selected from C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 10 cycloalkyl, C 6 -C 14 aryl and C 5 -C 14 heteroaryl and wherein R 4 is different from each R 1 , R 2 , and R 3 , (iv) optionally at least one further additive.